Table 1.
Baseline Clinicopathological Characteristics of All Patients (n = 7)
| Characteristic | n (%)a |
|---|---|
| Age, years | |
| Median | 67 |
| Range | 50–83 |
| Sex | |
| Male | 6 (86) |
| Female | 1 (14) |
| Tumor histology | |
| Classical variant papillary thyroid cancer | 2 (29) |
| Tall cell variant papillary thyroid cancer | 2 (29) |
| Poorly differentiated thyroid cancerb | 3 (42) |
| Tumor genotype | |
| BRAFV600E mutation | 7 (100) |
| Prior treatments of 131I per patient | |
| 0 | 1 (14) |
| 1 | 6 (86) |
| Other prior treatments for thyroid cancer | |
| Doxorubicin (concurrently with RT) | 2 (29) |
| VEGFR-targeted TKI | 0 (0) |
| Sites of disease | |
| Local (thyroid bed, neck nodes or mediastinal extension/nodes) | 7 (100) |
| Lungs | 6 (86) |
| Distant nodes (hilar, paraaortic, subcarinal) | 2 (29) |
| Soft tissue nodules | 1 (14) |
| Bone | 1 (14) |
a
Values are given as number of patients (%) unless otherwise specified; percentages are calculated based on the total number of patients enrolled (n = 7).
b
Poorly differentiated thyroid carcinoma was defined by mitoses and tumor necrosis (11).
131
I, radioactive iodine; RT, radiation therapy; TKI, tyrosine kinase inhibitor; VEGFR, vascular endothelial growth factor receptor.